GlassScriptPhysician profile
Kaleem Ahmad
NPI 1629065982
$13,733.45
in general payments reported to CMS, 2019-2025
87 companies · $2,079 in 2025
The $2,079 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,152 · 2020: $1,378 · 2021: $1,522 · 2022: $2,075 · 2023: $2,307 · 2024: $2,221 · 2025: $2,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,426 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,426.27 |
| Education | $179.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $938.75 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $897.92 | 2019-2025 | Kisqali, Piqray |
| Astrazeneca Pharmaceuticals LP | $775.98 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $710.44 | 2019-2024 | Krazati, Opdivo, Augtyro |
| Incyte Corporation | $705.97 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Lilly USA, LLC | $515.81 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $505.07 | 2019-2025 | |
| Pfizer INC. | $505.00 | 2019-2025 | |
| Janssen Biotech, INC. | $478.54 | 2019-2025 | Erleada, Darzalex, Imbruvica |
| Seagen INC. | $471.09 | 2019-2023 | Tukysa, Adcetris |
| Daiichi Sankyo INC. | $406.64 | 2019-2025 | Enhertu, Datroway |
| Celgene Corporation | $374.05 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $356.01 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $329.76 | 2022-2025 | Fotivda |
| Genentech USA, INC. | $326.19 | 2019-2025 | Venclexta, Polivy, Phesgo |
Show all 87 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaleem Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.